Kim Hyun Kuk, Jeong Myung Ho, Lee Seung Hun, Sim Doo Sun, Hong Young Joon, Ahn Youngkeun, Kim Chong Jin, Cho Myeong Chan, Kim Young Jo
The Heart Center, Chonnam National University Hospital, Gwangju, Korea.
Cardiovascular Center, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
Korean J Intern Med. 2014 Nov;29(6):703-12. doi: 10.3904/kjim.2014.29.6.703. Epub 2014 Oct 31.
The Korea Acute Myocardial Infarction Registry (KAMIR) was the first nationwide registry data collection designed to track outcomes of patients with acute myocardial infarction (AMI). These studies reflect the current therapeutic approaches and management for AMI in Korea. The results of KAMIR could help clinicians to predict the prognosis of their patients and identify better diagnostic and treatment tools to improve the quality of care. The KAMIR score was proposed to be a predictor of the prognosis of AMI patients. Triple antiplatelet therapy, consisting of aspirin, clopidogrel and cilostazol, was effective at preventing major adverse clinical outcomes. Drug-eluting stents were effective and safe in AMI patients with no increased risk of stent thrombosis. Statin therapy was effective in Korean AMI patients, including those with very low levels of low density cholesterol. The present review summarizes the 10-year scientific achievements of KAMIR from admission to outpatient care during long-term clinical follow-up.
韩国急性心肌梗死注册研究（KAMIR）是首个旨在追踪急性心肌梗死（AMI）患者预后的全国性注册数据收集项目。这些研究反映了韩国目前对AMI的治疗方法和管理情况。KAMIR的结果有助于临床医生预测患者的预后，并确定更好的诊断和治疗工具以提高护理质量。KAMIR评分被提议作为AMI患者预后的预测指标。由阿司匹林、氯吡格雷和西洛他唑组成的三联抗血小板治疗在预防主要不良临床结局方面有效。药物洗脱支架在AMI患者中有效且安全，不会增加支架血栓形成的风险。他汀类药物治疗对韩国AMI患者有效，包括那些低密度胆固醇水平极低的患者。本综述总结了KAMIR在长期临床随访中从入院到门诊护理的10年科学成就。
